MedLumics New CEO and Board Member Announces 10 Patients Treated in First in Man (FIM) Clinical Trial With the Real-Time Visually Guided AblaView PFA System

Contributed by: Business Wire

Logo

Tags

Cardiology

Biotechnology

General Health

Health

Medical Devices

Hospitals

Clinical Trials

Other Health

MedLumics

More Like This

PR Newswire associated0

Field Medical Presents Late Breaking Field PULSE Trial Data at AF Symposium 2026

PR Newswire associated0

Precision Redefined: LUMA Vision Completes VERAFEYE™ 4D-Guided Persistent AF Ablations, Demonstrating a Significant Advancement in Simplifying Image-Guided Cardiac Care

PR Newswire associated0

FIELD MEDICAL ANNOUNCES FIRST-IN-HUMAN DATA FOR FOCAL PFA IN SCAR-RELATED VT AT HEART RHYTHM 2025

PR Newswire associated0

Field Medical Announces First-in-Human Trials for Groundbreaking FieldForce™ Ventricular Pulsed Field Ablation Technology

PR Newswire associated0

Field Medical First-in-Human 6-Month Data Selected for Late-Breaking Clinical Trial at VT Symposium 2025

PR Newswire associated0

Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

A New Hope for Atrial Fibrillation Patients with Breakthrough Catheter Technology

PR Newswire associated0

Biosense Webster Announces CE Mark approval in Europe for VARIPULSE™ Pulsed Field Ablation (PFA) Platform